# Pfizer in Podcasts, Mar 23–29: Defensive Hold, Dividend Strength, Limited Upside > Weekly podcast summary for Pfizer, Mar 23–29, 2026. Body to be imported from the source email. # **Pfizer Inc. ($PFE) - Investor Newsletter** ### *Podcast Insights & Analysis | March 25-29, 2026* --- ## **Executive Summary** Welcome to this week's Pfizer investor newsletter. Based on recent podcast discussions, Pfizer is being evaluated as a **defensive dividend play** with improving non-COVID business momentum but facing headwinds in high-growth therapeutic areas. The stock has rebounded 8.59% year-to-date but remains a "hold" among Wall Street analysts. Below, we break down the key insights from recent podcast coverage. --- ## **Featured Podcast Coverage** ### **InvestTalk - March 27, 2026** *Episode: "Pfizer Stock Analysis: Q4 2025 Results & 2026 Outlook"* **Key Highlights:** - **Financial Performance:** Pfizer reported Q4 2025 revenue of **$17.6B** (beat) and adjusted EPS of **$0.66** (beat). Full-year revenue declined 2% operationally, but non-COVID revenue grew **6%**. - **2026 Guidance:** Revenue projected at **$59.5B-$62.5B**, with ~$5B from COVID products. - **Valuation Metrics:** Forward P/E of **9.4x**, dividend yield of **6.4%** with a 58% payout ratio. - **Analyst Commentary (Luke Guerrero):** > "I think as a defensive position, I certainly wouldn't be adding any more here... But as a defensive position, I think that this is a solid name to keep in your portfolio." **Investment Takeaway:** Pfizer is positioned as a **stable, income-generating hold** for defensive investors. The reasonable valuation and strong dividend coverage make it attractive for portfolio stability, but limited growth prospects suggest no urgency to add exposure. --- ## **Key Themes from Podcast Discussions** ### **1. Defensive Positioning & Dividend Strength** Pfizer's **6.4% dividend yield** remains a major attraction for income-focused investors. With a 58% payout ratio, the dividend is well-covered despite near-term EPS headwinds. The stock's year-to-date rebound from ~$21/share (mid-2025 low) to ~$27/share reflects improving investor sentiment around its non-COVID portfolio. ### **2. Non-COVID Business Momentum** The non-COVID segments (oncology, vaccines, inflammation, rare diseases) showed **real operational momentum** with 6% year-over-year growth in Q4 2025. This diversification is critical as COVID-related revenues continue their structural decline due to patent cliffs and market saturation. ### **3. Competitive Challenges in High-Growth Markets** Pfizer is **"nowhere to be seen"** in the fast-growing GLP-1/obesity drug market, where competitors Eli Lilly and Novo Nordisk dominate. This strategic gap limits Pfizer's participation in one of pharma's hottest growth areas and weighs on long-term growth expectations. ### **4. Consensus: Hold, Don't Add** Wall Street consensus remains a **"hold"** rating. The stock offers stability and income but lacks the catalysts for aggressive capital appreciation. The recommendation is to **maintain existing positions** rather than deploy new capital. --- ## **What We're Watching** ### **Regulatory & Policy Environment** With **Dr. Marty Makary** now leading the FDA and **Robert F. Kennedy Jr.** heading HHS, the regulatory landscape for large pharmaceutical companies could shift. Investors should monitor potential changes in drug approval timelines, pricing pressures, and vaccine policy—all of which could materially impact Pfizer's operations. ### **Pipeline & M&A Activity** Pfizer's ability to offset COVID revenue declines depends on its pipeline execution and strategic acquisitions. Watch for updates on late-stage clinical trials and potential bolt-on acquisitions in high-growth therapeutic areas. ### **Obesity Drug Market Participation** Any indication that Pfizer is advancing GLP-1 or obesity-related candidates could be a significant catalyst. Currently, the company's absence in this market is a notable competitive disadvantage. --- ## **Competitor & Peer Mentions** While this week's podcast coverage focused primarily on Pfizer, competitors **Eli Lilly** and **Novo Nordisk** were referenced as leaders in the obesity drug space—a market where Pfizer has limited presence. Eli Lilly's CEO **David Ricks** continues to be an influential voice in shaping industry expectations around GLP-1 drugs and their market potential. --- ## **Investment Implications** ✅ **Hold for Defensive Income:** Pfizer remains a solid defensive holding with a strong dividend and reasonable valuation. ⚠️ **Limited Growth Upside:** Expect muted capital appreciation given competitive gaps and declining COVID revenues. 🔍 **Monitor Pipeline & Policy:** Watch for pipeline updates and regulatory changes under new FDA/HHS leadership. ❌ **No Urgency to Add:** Current sentiment does not support aggressive buying; maintain existing positions. --- ## **Bottom Line** Pfizer is a **reliable, income-generating defensive stock** suitable for investors prioritizing stability over growth. The company's non-COVID business is gaining traction, but its absence in high-growth markets like obesity drugs and declining COVID revenues limit near-term upside. Consensus remains a **hold**—maintain your position, collect the dividend, and monitor for pipeline or policy catalysts. --- **Sources:** - [InvestTalk Podcast - March 27, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiGpfqmMDgwzlX5exYp7NkAqUXPXPzD7bRdxC-2FzSbs4J-2FXBZaTB3NhF0vDIk8WH1EVfPWirZgO1w-2BYqqPjb48bxlt9gh2mdmx9avuaARdJpcg-3D-3Dr0g4_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KCxJJ8bpwXIdtKGssA8-2B9DsAAOWGdTlQ8eaxSiVgL8PkCojr0R6mS6Ug5m8mqBvDYEcGzfTLzQcMIp7uFyTUsX5WhWBMXhrv3JUdS10p-2Fi6D5IeduU2P9ElceG-2Fumz0vuA-3D-3D) --- *This newsletter is for informational purposes only and does not constitute investment advice. Please consult with a financial advisor before making investment decisions.* ## Additional web sources used: web[1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIIi-2FKWJcxvH-2BAFB-2FjDdsg5-2FpP8hfJ-2FF7iK9wSwhJfPzNZz4c6E62mDyG-2BzUjdfPUHV3Wqfo8bGbDb-2FYvBcrd9u-2FfxNRzIM5N8x1MVySKOU1pPHljRQXDbhsoainBMkm9VGsPF-2F1AToU6kBNN5hfGsNrGC-2FhgaoU3rCsiAvFMHuR0-2F9vfWd-2Bi-2FyXGYRnI2mpIdpKNIUYrzq-2BcyV3riazNTjhvwqyxDGAlpt4svSQ-2BZ0nH-2Fx2JgeXygkck-2F5vTYM7kFKjVoNdWC-2FChMycQjNFwYYg-3D254E_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KF1-2BdkAZQzmJeari7wu9tytmO7PaHbXAzYQwPKZorIY4LIBLytqPyjlfpaPRKO1VleiDrzfgBxjgpKdKvcsokB5QG3GDmpL-2FEshXof627ZR5xnsN1lt-2BLWD4u7crUv31Bw-3D-3D), web[2](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIIi-2FKWJcxvH-2BAFB-2FjDdsg5-2F1NBfL3EmHKHt41DMAWC1yGnbqE2-2B0mxyqzJKIpKDIJPlei9NB0VC-2BPf-2BLtBAGRcGOw-2BULaPMAxgLkOUC-2BSRgVItQuAn3jqD3E0J1OVjxFajcBMT36N6SBaCr-2B73CZ4SsuKYx5SQAdtLug61UGSpMTM9jPxcnmSlnnaFa-2BPi6bMAkVRUgVCA0SLNKZoJVb2gmApWbtgcQJzr9h6E1cx8mlIL0X2iMFxLX-2BZZG3mg6dmA-3D-3Du8dh_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KLHqAi6cQ4R116NwrqdnXJ4VFFF-2FPPTIDHPcps3gRzlsgBq-2BWuhClM5wTWd2W1-2BYXX-2FRF9aaksF1mfEoEh4MLKuibhVQpeIqchb3VFW4IjzHcKOMzb1cRjoFNBDBu3iMoQ-3D-3D), web[3](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIAY79tKsdLUh-2FcWkWeKJlY9LzIdKIqnfDs3WS5BadKsbCZLaYj9QEtU-2FOzmDlSz8QfcaOs8gN7rpVJj830ODU-2B1WGeRXGaou8PgSFBXQiOgY6vJi-2Bu6jEbfAz-2Fa-2B3AEXpE5UgZwTOLjHSG-2B583Zf-2BtBz1N5-2FxYsMjJc-2Bl-2BDiE4klQVozlXFhRHJfGDWnHt2TwX8tUr-2B1flYPZsllgizVqTNmedAhvuYUz5IBEXWN267sv5JYBeVNxtelPUv2tqJ389KxOm91W7eH8X-2FCkStqlgvD92sqQ3y-2BD0a2MinNOD6ITdmViWsrcE-2FiHXDFt6xAiA-3D-3DzfxV_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KE813PlxMwHbrBmr0AidKbYzYls-2BnOGrTkxwdQoe1nmHtgZ8zk3vjMuxu-2BPOpPFqj2DsveZdNg6SGpJzQ0oVDZZKqIKYe3qvDMo3mhrg1D44ppjNA9kgS-2FZx5S15c64HsQ-3D-3D), web[4](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIAqGQxa-2BI8AB6CsUhVOaW2njaHnt5mej5Y5YvKGAT6SHvR5uUqcxOconTE-2FGVbORFHyzV1tMLK7ffQZigEpjfj9FPfY97F97i3Wr6U3LVTkv2SunR3YUDd4eNgiZKJXtzSNJlRezoCfCZaMEUaDYf2-2FfE2VTnXV-2B5HI844-2B0TIoT2WacEB35MqTKRYJ0so5y0aHNTIZ6A7ly-2FBlJNgNurPs7jzwXmsCUaD4eORldpzraB5-2FbIvi4NhEjIcnEVZgmHgYhz9MRwVSOk5tdECYsl9Z72bwsyV94xgpi8Y-2B35N9i48Qe_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KH7kztbVAswtbYfDKB7cpKfJOAWBMEQn-2BsmeOwSRlq4yYtr0DxWn0-2FNvymiSxZKVoRZv7cQ51fEfu0I2-2FwIiAyzkDR7sO49rdgVA-2BxH0BNWkVhVHaFAdqPJo6XuIrBGE7Q-3D-3D), web[5](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIIadV8LnlF128P8uFmsxsrvVWDqij0xaAXaqsLQ6ltC-2B07eeTw0DzBMnV5QQ7umYsW3tMvzy941Gl863o0doXrsT5ITJjUYMGZeyeVjzOb3WztQs0x9ZzfdukGg0W46bbnjmztiImt5umhkWxEznXpR-2BGJHmBF-2FiOPzv0s3LaCiZ5FCs9A-2BOAOAQcKjSGhQJGLzopZE16cYWa7JBjF0W92lAbPieWFc7QcbDBy4LFOB9-2FBfJwAW24SHJXp-2BCZP7qx6rYAH-2FjL6SBH8AbXAH-2FOSjlWe8XQkLib3-2Bsy1l8m46vhnw2_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KNxa2liZ5LtG13uGKF0c3M5QPnU-2BwwqOIDzQt44alALq-2B-2BOQbP3kjPaLu7jb64oHYKVOYAvLIPyI70OuB6-2FXKUDihhllzJQdpmX3X9mDLP1IdoIlGKx-2F-2B35YCfZKg3k75Q-3D-3D), web[6](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIBQcVwK5v-2BIUdBq9ionIyJnvCvZAmuG6j3TLrd2Jfpy0Dm0vz8FDm-2BN0LkAAM-2BOqiRm5ayKspVdncq2BRz-2FGPbZGc5UMufD6n7eoPM8FrjQzyGDyAWsQ48GPbN1y1GrERFn7BahNQi1V1GFz-2BWtW8nXyIXk440J4ep-2FJLia0LI3EeRt8WIxtUHE886mHYg9IdEFHoGQCgm5ndznDEWavVvFByKfgtUEY3o4ZHEI7N-2BjD78EM_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KKXNeyobITfsOcBff0Uxu1J-2BTuCSzQ0r1GtqyZ0whuETfiLAxME1BGs5li3-2FkrQXnUEvSPjA1wlEB-2BzSIoQi1OIC4Ti29ib87lgl6Iq8sGQ-2FNj1qwHcZdiGDL92ctyIupA-3D-3D), web[7](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIK-2BTR-2BvEUwn7M83URylcYRGIEdeKyKSyTJLtlg455hAMVZsYSR43rRJKR0LtQq8EeANQ8RcueIBBAF-2F7tv-2BEycmn2n5u0hjEJ6DNk8COmLNZj4ePA0-2FgI5dJGG3e-2Bkpsj-2Fdk7Ubz3-2B-2FliLWTQroJlUtKnP55hNPO4ZRhx4Ry2iwRPyF9GJMY1-2BrUgvecwQtpXd-2BGQjlI288VO0qb01HvHhvIPi2oMof0uINDl4NmchBqGFZJ5H8Qp1IS9IdVpK3XMQ-3D-3DE7mt_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KNrcNraWOvDJDd9LSX5q2v1zVVspXQwFXlGzr688uYTXRz6JRdON6iqeSPaAEQc-2BhWl5rIDvTDH-2BOK8ETS3om1uoEz4rYd3qb08TOMrFFmfS0uPBRENnZU2Fuble5u9k5A-3D-3D), web[8](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIGZKi3A8QKFAOl-2Bx5p5QrNPhgrFi4dK6vNEbr5Ke-2BldDKcx2zvXV-2B0CygQWwPbes9JLcD4L9xSVk9101LG8CPTO2adJvlQ-2BF7UOgS0qoVYsGkytiQbF1SN5AhHXPTQsPTnBSi2ZV5unLzqXaPwphypLFlWwl-2BRLqG06P8EyXGIkHFJTVdq5K0Lyd0pM03zkFq4bUfBk8ZaLBM-2B7VtprGwZOmxkGztp0jIrLRgA8LdCCrMKj8_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KHjLyOLW-2BnNpfax0D3-2Fu9Cpv1qPqolyb5mPY8JTFGigei2ILvQEIyhw3VL2gsj430Km9CTckDfHeW6w7fHM9TfKp7RZlMtTLBJuCbonX2tzUDC3nj63-2FnbpP88f5n4clMQ-3D-3D), web[9](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIHODwTPLo0QuH5Crzq0VjVF0bVaMrfDP-2BfF6bTYNNz5AboaiIFt73ywStsYWHxpDYBHOzLeEpDnA971JRezstE8o8cRU01qmJ-2B1zNplHlh-2BeFdvOw60F3n7wS5AXyinlPWS-2F-2F-2Bw7huUHySOVdngQ3xn0ERDcJxCqFm6TRA-2B6aLSh8egt0oPNTJIx-2FgcrXhORu4HQshGCr5SQBqJbh7Yhs4E-3DIH-O_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KJpPqf6p2Mn92Ogo-2BeTcANNJ9lG3mNG1QvBqFliecR35srcvTQa4JjxHVyacdorvXSIXflcffYWTe3kjDS0PYU5I3nkjeEErN5-2FX5xnwzkTBVZGD-2BCPkGWAJnDIc4VmObg-3D-3D), web[10](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIKuPGPKhkPh7oHts8MsJAyuTy4m8ni3bT6hs-2Fi5ElTocfX5HPI3zW2f-2FKYqfr70qV9c-2Bhmt4iguwfPWebCH5dMT8DP8QXIquUOirETWL702jtSv8tMRWG0G-2FE4hXuFhq6w6186kBSWP-2FNtV3UMfm3KUXnXmghq4JTxvcPDWhi9ob5K8Irf7Jz5F6NiHPl5ZNAe9VKCvOMiBzdg7csiN2G1tIv86xeRrG0AtU2VOU63p-2FX28wkut2heSN6goCAZUAsqnWjPtLp1V2HKbPgfGCF0I-3Dw6zS_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KA-2FoYP9UmJsBE1jzZLv2VpJbKGrNqqNuDsXWjjnJjQPdlHAA9mU03Cbgkx0piObPwHC53Bjd40JPYfoNLrX8ZXznAEml5odfGtCVvUB0pKT8ubzBVSwOcdeKZGldK6incw-3D-3D), web[11](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIBq8-2Bp2ztfwFG2a8c-2F2AoivaRRSZ1WltHBFaNio0OzrimZou1DMSSmFqavqEnUxBgJZxkD7a47JwGoblpbhKLyjsT6W959bkoMPSvdZQuEKjpyTV6J1JuVsejBW-2BXPYaaNg2H5ZxGgxG22loi3p-2F027mc7Kzb1EOyNwJK7cSwGChqpJAlCKQloKYA306fP99l8w37M7Y4rsyVhNeRXjgfk9fTvIYoZbvYIsGaKFSOUdoQ1YIqziWJVVfPZy0thYuu6LJLx-2B-2BnIitfHRNzxhCF3aOLQQwG-2BeAPHgYabco2lY-2FBIdUEfVS9GNttYk1uSFMijwJBbJs-2FTq16PUVnsgV08DdLbGhqQiNihpOJNTfZB-2FFpn-2FpWZs4cpmonW05Og71e9ALgzdNFrYY5PNMJdNgC-2Fw-3D_gk-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KHPpsE9rjDumViHbT9m6G7El2P2XxuWeo6XEwn3RtgG876QPqLi62ZaB94AO1qSxOaeRUItRylFr-2F-2FFpzbTiH9uaWJ2MLcbrqkwZxSJ9RvqwODuK2bJxa8e6glq0Ea5aZg-3D-3D), web[12](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIEpAxSbzF2SFg22DAsrtdG0hMxeLT4T2WdhS-2BKSyZ9QZcbVjGK8OLayPltDdxjx1pa-2FIoQQ7AcRZ-2BMOMOlQPXHIn-2Fur2-2FEmhZX45rj7Yvf5mLEuvJWdTqBJY51r3CMEySXpdLbI34gRiQIIxYJDthtLXLp5PsBE-2BDaHZ57an35OK9VwUHKRqFZ5rPR2tyx3aibrMLp7zhmSbFqNAc0TH9riF2DWV7-2FfeR0GqNqqE-2BicvIGlfOtrtM6dm9y9O2Mq6EmXv-2FlV5DQ8cAbjvfEr1IJJzRXnv-2B7vYxrhT9vt5bsrOAm8h-2Bzv8eRTJRXXFIbHX2A-3D-3DtoUT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KAifDcDeLSiUCEKqes3qLCXhXZdbHE4zuDjhLvhH7OWHjt-2F0W2pA4h92KQ2qVIXH0Sy-2BJdeI645MBO7tZPB4JJjJ3CMUayYBdnluCleR8bWCxWHZgatYsXn6FXpuTxbuyA-3D-3D), web[13](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpINgvsZ4VFjewSV9j14qrnupg6OjAXfx2xqnduuSHJxzkmy9LmQTvSatUEndxmm-2BCsxMpAyFIRSDz5CdWRx8ywUFGRVvSx2PKjy5vHfpqEjsCDRAoU8ao5G6QmS0xzXOlaJa05Jnm5yZQPRWX7PFGJyhJ1bIR4U65qSwybQ6rE7ZpL7j9Lb-2B2n0-2FzmzUPNl5FnNwXuRT7GkFtL40RvQ-2BnXQLCqIqTtM9t3-2Bhu2OMPMj7wWJ9gWo96PozQqq8c8SAEkbQ3Nbe4VbAS3KcALblNvYGblEAq30s7CRsp4RbxxY5SRQPTOzyMGvMlihAWW46fDWuaSbP3gNdP-2BpU5loxE5Dk-3DWcWx_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KAY7-2FNbMYV9p4UShAj-2Bm4-2B5eVDn08ufKSRrZE9-2BRIcJhBk3QtFxsdzv7FYQ5csJ889D5nt17185g9np2-2BplKv-2FYuS2n9BmfsTsJWf676wuIDnpSu0ZemTXCDyPkNKgWgyA-3D-3D), web[14](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIPP1EbOsPuW10U7TVC2rL6z2TNxBTtuAU-2BBZsn6NUqRQcjKbVdLfWF237jl4gPstSkfXWsfUuTiI1A29APu2rWC-2Fgs-2BGFfO3jtlS4Bw5eAj2IsL4pLMM42DJJj4XnH09H3WuY2siKbfUo9Th2OGGR2rw1ILxxNsRrwL1rRGguYZGe5uBKfq8sdT-2FY4GCkmYxhDuxqQerCmBCg6YQY7dfddTsue8tbbbN-2BA68PPF7texgPqXsWzqkSrSez9wEAGtW7jNDLmi3319DXA4psiOphS8IdaL7zFGEBg0-2FxlqDUFYYCwdAL0lANFHIGzY63lvP6CfMUzXgkMdjNBMW1zOzKRJN79cw4pbqRptwV4Hgsz8Bav2K_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KH-2Bt9NoQ8JR6O1b2GmQfod34qAHsdX5McGniIQfzQTG4OLnHLJSvH8ISeNC6Vb9zX-2BtCT1SJkODyni3hb8x9beGSiRen2wsblJnOjbdXoIueYzQRqu9kH2IF648tkn9-2FxA-3D-3D), web[15](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIKacI-2BZMycX-2FA8kT3HDgl0RO7jXj-2F53s2yC0ZBeyLLx6pumyKOq8KIaXQVPCzMyAkvVv9gN-2BQdc1bvh2SvFekJfge1fRKKA1oqCcFTAt8G9hR0vei-2BE4WWlTICLSECyt-2BMfX1JeH4FoPw7gTYhDW8dt1MVTQYpoZ1qMLvMPHUFkqF7GKUL-2F87DYyrWAYhTlf9KxJDAEkJB3CGr-2F2i9-2FvSqA3dzb-2FTYgwMP4cumgZToUR6whhKcor4-2BhOiQw7tCrQYOYG3AI88MndjtV1vun7J61nFQ9gE9aSf0p8l0IpSW8yYAZ-2BBqNx6wx-2B9wxze0rVPQVb4B8-2FbBQriiIFCls-2F478-3DTSeB_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KArP7A0cjqMeubbOU4euWqX6UH83D5t4R0ebzfnYcdvyFJuD2un-2B6EsK-2Bw50e4oK4T6g6F9KHTXdubJrfLPG3DPqbYXYhTALOhrZ3AyPiLXMqRRB3tU6bKsVprlELtyRJg-3D-3D), web[16](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIKPp8hm3QlLR4rbhkQrWe7GUomOBX4BzKJatgd-2FSvsZjnPU-2BKdUeRgcQ1uAi9M-2FAAKfuxNbb-2B1oEszFybjd1wvTjWnTe7XQZyAZUDIP7xDfb9XyYbeLEUjtzv-2BUZL1h8RkmgeyM-2B4YWdR572HABkSqLZ2l4vGfhoPmI-2BHTR-2BmW-2Bc5JBr78Pze7U-2FonDfOWmUbSI3Ffy93lD6P9uDtmdXYW1U5JfNwWXGNZPqU9dI-2FKh1GyWn0vWSOfZF2cI2ZVWjWsQl-2F0Fvz2Xn4wmNafYqnzM-3DDWGq_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KOhS-2FAmEJxFId7gl-2B4OkKh792oWOIrxNMkg2h8TGjRj4zV4dBvQSvEE0AjaNush936FfiFNP0R4xWFPoNlbriTuf4Qyilj-2B9B3E-2Fbz6Bw0gCSRhNWrF0S0Hk1A9Jpm2WQg-3D-3D), web[17](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIIm54qlckRiCpF2KErQnrhBt57ff-2BT7Ei5Fe1Ins18MWVj89aYRKJSrcNR2moaLskgSTW-2BxojkZhUm96hOCvi8EaFsefuLYf8FtdHBh6ux7sZP2QkleIfsFyDt4FbsB7Lw434pw8DtQB2tmGqix3D7xupQQFGTQU6mhDf5CZkHzU1KeyKKlcx3fQ6nVhGaGe-2FUpmxWYiqjzK6QoWe1SKrKg-3Dyyq4_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KPxNP9mgLXqQfuje9LKSSsOi9SMMeeinMlHw7N7sqMBPVrB5sPvQLKsdyltMzb2XCRT1PgeDv5gTIaxsZep6Ypca4aCzk-2B-2FpmYFt-2BAUYit6T6iQio9xzwhOD-2FikTCTclUw-3D-3D), web[18](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpINBijWYRMnr10omr8NdML1BfCGzm8g9E4HNXiN4Wpu-2FI2vJbzyc3fGP42iLRF9wB1zdBzLBu-2BvhIukZfaQwda7UeQkAQ2i-2FmFnvDYavSFZwZdUTDzLVY3bIoEdCLsRbGwVgIEtffY1TV-2BQonN2sH9-2Bms6HaSLxdB8UMOunbg3SEuahBJ2QRaRkyRB1sPpAD7LZQi0EtFk-2FhibznagGGqG45Lg4SL8aoSRWRbhPscZxFX9WEN_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KF19ba5EXnhbaxH-2FunXu1CGJns3q1b7ybINzo4qkoFtvd2q3OGarKX8XV-2BsAYOFc4rIiHMEkftQY7MxU5UeUkhjPRWJvRgmWswrGPb2CUCjyRR7wjc3tBkJk9yWg5h-2FU4A-3D-3D), web[19](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIKacI-2BZMycX-2FA8kT3HDgl0RbAM-2B7DIAYH4lBb1ca81UjGD-2BlTN-2F5F1uKbMlRRRD2OlA-2B1vvgKA9qFZzvPLrXzKUEBUCpinFvYlz27sGnT8ZjBoB6MZWfAnEPWT4A9dLsN6TQ7VOOn0pwlGM7c4lvbdWJ97a01UIXHkqgu1dDQ61xNkJVSRA3tPEAkdjDbgK1FxW9qAH9TuqN8yanNLJULlkBEZkIFWEBZ0DOaH0NRkT70U2PQBJg1MtF4qIgZkyV-2FW3pWnveuto4YKcZk-2FnGdc4Y5zvrVW7t-2BmN42D8cCJ6v9SWj3TYXCYcAyH5AWQdwJc4PzUCoVsuJ1LhJUGZbuZrsqogri1Ok2qTLWoCqHq795BXQOOpeGxyUrwZL1upxDmolh-2FnoYN1UZbcfkY9Mq-2F8-3Du1j7_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KDkiqQ0F0AwqobXf4EK2IPbOTNFZsR8PjJCBS-2FMyqJWBD8Uqgu5rNijBzEbNoS3eit788CJwHOqO7-2FP-2FYNwmUf-2BXxXvNFHaqWSnsR5wh01MsH1NpDlfEpDDxqVRYna1v5g-3D-3D), web[20](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsLjCVq1DyuRL4b7YHhJiJic5Sj6qMmkUtKv-2BmREm8eAgvTo0ZOqkVUq9nUDTfWpIA-2Fu87d2anDSmWv2yEJXsZUynmqtBkW1JGJ6DtuijqS2WKHii-2B4FxzXZPtzw2Rrg4vggpFPPy-2FDxjXAwmvRxHhS-2FvHmVe0BVWM-2BzvrIxl9SgNsCLIT6yTgTKXq270SAFGA37NoTH9ZJ8rXhsTPUW4srf2yBzCPHkQWJfWh-2Bf7zRRvvCCn97SEM-2BWSGM1t2hSf2QJLjDY1pWRagyONMfuC0vFvrSFrBEGegdMFSX23N0sVAlDzZWRv9qJNBhb4idf9IcPYTes2yl-2BUXJCpjBrf6pybVeeqJXqe6aex87ewWCdv6S4FlIqSA8fCjZgzTg1GQ-3D-3DyN5j_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVeZ4H9BUrDYZD83uyeG6n-2FE0agaxK1I-2BRYQXtFvQN9KCpcuf3iM7B5caU99hZj-2Fny-2B8aK-2BAdp9gNXKRpUNzPIpTmFPgQx6wDQdZ7BAQcBUBJC82jfiYLpNa4wwNhi4-2BcZgKHZ6Mky67NvT6iVM8j5Fdo5fTB1lq-2FGtuQW-2FE3EKZA-3D-3D)